国际标准期刊号: 2277-1891

国际先进创新、思想和创意杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Potential of KLS-13019 to Serve as Non-Addicting and Non-Opioid Option for Neuropathic and Chronic Pain Relief

Dean Petkanas

According to the White House drug policy office, drug-related fatalities increased by 11.4% year-over-year in the first four months of 2020. As opioid overdose deaths skyrocket across the U.S. during the COVID-19 pandemic, emphasis needs to be placed on proactively creating non-opioid solutions for pain relief. Kannalife, Inc., a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, has been working on a non-opioid solution for pain through its laboratory-created cannabidiol (CBD)-like molecule KLS-13019. In research funded by a grant from the National Institutes of Health’s National Institute on Drug Abuse